NCT00490399CompletedPhase 2
A Phase II Trial of GEMZAR Combined With Cisplatin in Patients With Inoperable Biliary Tract Carcinomas
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 39
- Locations
- 2
- Primary Endpoint
- To evaluate the response rate
Study Overview
Brief Summary
The purpose of this study is to evaluate the efficacy of gemcitabine and cisplatin in Korean patients with biliary tract (bile tracts of the gallbladder or liver) cancer.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologic or cytologic diagnosis of adenocarcinoma of the gallbladder, intra/extrahepatic bile ducts or papilla of Vater with locally advanced or metastatic disease (at study entry) that is not amenable to curative surgical resection or with recurrent disease after prior surgical resection or radiotherapy.
- •Disease status must be measurable disease defined as: Bi-dimensionally measurable lesions with clearly defined margins and two perpendicular diameters that are clearly measurable by following:
- •Computerized tomography (CT) or magnetic resonance imaging (MRI), with one diameter 2.0 cm or greater and the other diameter 1.0 cm or greater.
- •Palpable Lesion, with both diameters 2 cm or greater. Disease progressing in areas of prior radiation therapy may be included.
- •Patients must have received no prior chemotherapy for advanced disease.
- •Prior radiotherapy must be completed at least 4 weeks before study enrollment. Patients must have recovered from the acute toxic effects of the treatment prior to study enrollment.
Exclusion Criteria
- •Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •Heart failure, angina pectoris or arrhythmia that are poorly controlled in spite of medication or acute myocardial infarction within 6 months preceding study enrollment
- •Severe neurological or mental disorder.
- •Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.
- •Poorly controlled diabetes mellitus.
Outcomes
Primary Outcomes
To evaluate the response rate
Secondary Outcomes
- To characterize the quantitative and qualitative toxicities of gemcitabine combined with cisplatin in this patient population.
- To evaluate the following time-to-event efficacy variables: Duration of response, Time to treatment failure, Time to documented disease progression, Overall survival
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
Chemotherapy +/- vitamine supplementation in advanced Esophagogastric cancer.Advanced Esophagogastric cancer.NL-OMON23015Vu Medical center82
Completed
Phase 2
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast CancerBreast CancerNCT00191451Eli Lilly and Company150
Recruiting
Phase 2
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT06298968Nanfang Hospital, Southern Medical University38
Active, not recruiting
Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic AlterationsInfiltrating Bladder Urothelial CarcinomaStage II Bladder Urothelial CarcinomaStage III Bladder Urothelial CarcinomaNCT03609216Alliance for Clinical Trials in Oncology237
Recruiting
Phase 2
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerGallbladder Cancer UnresectableNCT06591650Fudan University33